The estimated Net Worth of David C Hastings is at least $277 mil dollars as of 1 February 2024. David Hastings owns over 9,593 units of Scynexis Inc stock worth over $254,670 and over the last 21 years he sold SCYX stock worth over $22,160. In addition, he makes $0 as Director at Scynexis Inc.
Sign up
David Hastings SCYX stock SEC Form 4 insiders trading
David has made over 11 trades of the Scynexis Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 9,593 units of SCYX stock worth $22,160 on 1 February 2024.
The largest trade he's ever made was exercising 275,000 units of Scynexis Inc stock on 13 February 2014 worth over $3,575,000. On average, David trades about 17,186 units every 136 days since 2004. As of 1 February 2024 he still owns at least 181,907 units of Scynexis Inc stock.
You can see the complete history of David Hastings stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Hastings biography
David Hastings is the Director at Scynexis Inc.
What's David Hastings's mailing address?
David's mailing address filed with the SEC is 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY, NJ, 07302-6548.
Insiders trading at Scynexis Inc
Over the last 10 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado, eMarco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
What does Scynexis Inc do?
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
What does Scynexis Inc's logo look like?
Complete history of David Hastings stock trades at Arbutus Biopharma Corp, Incyte, Scynexis Inc, eEntasis Therapeutics Inc
Scynexis Inc executives and stock owners
Scynexis Inc executives and other stock owners filed with the SEC include:
-
Dr. Marco Taglietti M.D.,
CEO, Pres & Director -
Dr. Marco Taglietti,
CEO, Pres & Director -
David Gonzalez Angulo,
Chief Medical Officer -
Eric Francois,
Chief Financial Officer -
Christine R. Coyne M.B.A.,
Chief Commercial Officer -
Philippe Tinmouth,
Director -
Jean-Yves Nothias,
Director -
Guy Macdonald,
Director -
Patrick Langlois,
Director -
David Hastings,
Director -
Ann Hanham,
Director -
Steven Gilman,
Director -
Laurent Arthaud,
Director -
Armando Anido,
Director -
David Angulo,
Chief Medical Officer -
Scott Sukenick,
General Counsel -
Nkechi Azie,
Vice President - Clinical Development -
Jim Maffezzoli,
Vice President of Sales and Marketing -
Eric Francois,
Chief Financial Officer -
Marco Taglietti,
President, Chief Executive Officer, Director -
Pamela Kirby,
Chairman of the Board -
Debbie Etchison,
Exec. Director of Communications -
Lawrence R. Hoffman CPA, Esq.,
Interim CFO & Principal Accounting Officer -
Dr. Rajeshwar Motheram,
Sr. VP of Pharmaceutical Devel. & Supply Chain -
Scott Sukenick J.D.,
Gen. Counsel & Corp. Sec. -
Patrick Machado,
Director -
Marion Mc Court,
Director -
Jr. Charles F Osborne,,
Chief Financial Officer -
Biopharma Partners Ii Lpalt...,
-
Carole Sable,
Chief Medical Officer -
Capital Ii Ventech,
10% owner -
Biotechnology Fund Fcpr,
10% owner -
Eileen Pruette,
General Counsel -
Genavent F.C.P.R.,
10% owner -
Mounia Chaoui,
Director -
Edward Penhoet,
Director -
Yves J Ribeill,
President and CEO -
Advisors Llcperceptive Life...,
-
Christine Coyne,
Chief Commercial Officer -
Ivor Macleod,
Chief Financial Officer